<p>安联资产管理公司在最近向美国证券交易委员会的披露中表示，在第二季度将其在 Quest Diagnostics Incorporated（纽约证券交易所代码：DGX - 免费报告）的股份减少了 21.8%。该公司在此期间出售了 84,694 股后，持有 304,361 股医疗研究公司的股票。安联资产管理公司在最近一个季度末持有的 Quest Diagnostics 股份约占 0.27%，价值 54,672,000 美元。</p>
<p>获取 <strong>Quest Diagnostics</strong> 警报：</p>
<ul>
<li>Myriad Genetics 因遗传性癌症检测股价飙升</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也调整了对 DGX 的持股。Twin Tree Management LP 在第二季度收购了 Quest Diagnostics 的新股份，价值约为 1,895,000 美元。J.Safra 资产管理公司在第二季度将其在 Quest Diagnostics 的股份增加了 8.2%。J.Safra 资产管理公司现在持有 2,553 股医疗研究公司的股票，价值 454,000 美元，此前在此期间又购买了 194 股。TD 资产管理公司在第二季度将其在 Quest Diagnostics 的股份增加了 18.0%。TD 资产管理公司现在持有 121,014 股医疗研究公司的股票，价值 21,738,000 美元，此前在此期间又购买了 18,484 股。Morningstar 投资管理公司在第二季度购买了 Quest Diagnostics 的新股份，价值约为 315,000 美元。最后，Moran Wealth Management LLC 在第二季度购买了 Quest Diagnostics 的新股份，价值约为 18,558,000 美元。88.06% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Quest Diagnostics 股票上涨 1.5%</h2>
<p>DGX 股票在周五开盘价为 189.71 美元。Quest Diagnostics Incorporated 的 12 个月低点为 146.91 美元，12 个月高点为 191.49 美元。该公司的流动比率为 1.09，速动比率为 0.99，债务与股本比率为 0.71。该公司的市值为 212.1 亿美元，市盈率为 22.72，市盈增长比率为 2.48，贝塔系数为 0.56。该公司的 50 日简单移动平均线为 182.44 美元，200 日简单移动平均线为 176.13 美元。</p>
<ul>
<li>LifeMD 因 GLP-1 业务增长而股价回升</li>
</ul>
<p>Quest Diagnostics（纽约证券交易所代码：DGX - 获取免费报告）最近在 7 月 22 日宣布了其季度财报。该医疗研究公司报告的每股收益（EPS）为 2.62 美元，超出市场共识预期的 2.57 美元，超出 0.05 美元。该公司在本季度的收入为 27.6 亿美元，而分析师预期为 27.3 亿美元。Quest Diagnostics 的股本回报率为 15.24%，净利润率为 9.01%。该公司的季度收入同比增长 15.2%。去年同期，该公司每股收益为 2.35 美元。Quest Diagnostics 已将其 2025 财年的指导目标设定为每股收益在 9.630 至 9.830 之间。根据平均数据，股票研究分析师预测 Quest Diagnostics Incorporated 在当前财年将发布每股收益 9.7 美元。</p>
<h2>Quest Diagnostics 宣布分红</h2>
<p>该公司还最近披露了季度分红，将于 10 月 20 日（星期一）支付。10 月 3 日（星期五）登记的投资者将获得每股 0.80 美元的分红。这相当于每年 3.20 美元的分红，分红收益率为 1.7%。除息日为 10 月 3 日（星期五）。Quest Diagnostics 的派息比率目前为 38.32%。</p>
<h2>Quest Diagnostics 的内部活动</h2>
<ul>
<li>Exact Sciences 为投资者提供了他们所期望的</li>
</ul>
<p>在其他 Quest Diagnostics 的新闻中，高级副总裁 Michael E. Prevoznik 在 9 月 26 日（星期五）出售了 227 股公司的股票。股票以 188.13 美元的平均价格出售，总价值为 42,705.51 美元。出售后，该高级副总裁直接持有 38,117 股公司股票，价值约为 7,170,951.21 美元。此次交易使其持股比例减少了 0.59%。该出售在与证券交易委员会的法律文件中披露，可以通过此链接访问。此外，高级副总裁 Karthik Kuppusamy 在 7 月 31 日（星期四）出售了 2,210 股公司的股票。该股票以 170.00 美元的平均价格出售，总交易额为 375,700.00 美元。出售完成后，该高级副总裁持有 8,450 股公司股票，价值约为 1,436,500 美元。此次交易使其持股比例减少了 20.73%。该出售的披露信息可以在此找到。在过去的九十天里，内部人士共出售了 53,186 股公司股票，价值 9,647,471 美元。8.16% 的股票目前由公司内部人士持有。</p>
<h2>分析师设定新目标价</h2>
<p>DGX 最近成为几份分析师报告的主题。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Quest Diagnostics 股票的 “买入（b）” 评级。Baird R W 在 8 月 25 日（星期一）的研究报告中将 Quest Diagnostics 的股票评级从 “强力买入” 下调至 “持有”。Truist Financial 在一份研究报告中设定了 Quest Diagnostics 的目标价为 195.00 美元。Wall Street Zen 在 8 月 10 日（星期日）的研究报告中将 Quest Diagnostics 的股票评级从 “买入” 下调至 “持有”。最后，瑞穗证券在一份研究报告中将 Quest Diagnostics 的目标价从 190.00 美元上调至 210.00 美元，并给予该股票 “跑赢大盘” 的评级。一位研究分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，十位分析师给予了持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 189.06 美元。</p>
<p><strong>阅读我们最新的 DGX 股票分析</strong></p>
<h2>Quest Diagnostics 简介</h2>
<p>（免费报告）</p>
<p>Quest Diagnostics Incorporated 在美国和国际上提供诊断测试和服务。该公司开发并提供诊断信息服务，如常规、非常规和高级临床测试、解剖病理测试以及其他诊断信息服务。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Quest Diagnostics 更好的股票</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>如何投资科技股及值得考虑的顶级科技股</li>
<li>博通与 OpenAI 签署协议：这对 AVGO 股票来说是一个巨大的胜利</li>
<li>投资旅游股票的好处</li>
<li>机构正在推动 CrowdStrike 的下一轮上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Quest Diagnostics 吗？</h2>
<p>在考虑 Quest Diagnostics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Quest Diagnostics 并不在名单上。</p>
<p>虽然 Quest Diagnostics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

奎斯特诊疗

<p>安联资产管理公司在第二季度将其在 Quest Diagnostics Incorporated（纽约证券交易所代码：DGX）的持股减少了 21.8%，目前持有 304,361 股，市值为 5467 万美元。其他机构投资者也调整了他们的持股。Quest Diagnostics 报告第二季度每股收益为 2.62 美元，超出预期，收入为 27.6 亿美元。该公司宣布季度股息为每股 0.80 美元，收益率为 1.7%。内部人士的销售包括高级副总裁 Michael E. Prevoznik 和 Karthik Kuppusamy 的交易，过去 90 天内总计超过 960 万美元</p>

<p>Allianz Asset Management GmbH cut its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 21.8% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 304,361 shares of the medical research company's stock after selling 84,694 shares during the period. Allianz Asset Management GmbH owned about 0.27% of Quest Diagnostics worth $54,672,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>安联资产管理公司在最近向美国证券交易委员会的披露中表示，在第二季度将其在 Quest Diagnostics Incorporated（纽约证券交易所代码：DGX - 免费报告）的股份减少了 21.8%。该公司在此期间出售了 84,694 股后，持有 304,361 股医疗研究公司的股票。安联资产管理公司在最近一个季度末持有的 Quest Diagnostics 股份约占 0.27%，价值 54,672,000 美元。</p>
</div><p>Get <strong>Quest Diagnostics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Quest Diagnostics</strong> 警报：</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 因遗传性癌症检测股价飙升</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently modified their holdings of DGX. Twin Tree Management LP acquired a new stake in Quest Diagnostics during the second quarter worth about $1,895,000. J.Safra Asset Management Corp boosted its stake in shares of Quest Diagnostics by 8.2% in the second quarter. J.Safra Asset Management Corp now owns 2,553 shares of the medical research company's stock valued at $454,000 after purchasing an additional 194 shares during the period. TD Asset Management Inc boosted its stake in shares of Quest Diagnostics by 18.0% in the second quarter. TD Asset Management Inc now owns 121,014 shares of the medical research company's stock valued at $21,738,000 after purchasing an additional 18,484 shares during the period. Morningstar Investment Management LLC purchased a new position in shares of Quest Diagnostics in the second quarter valued at approximately $315,000. Finally, Moran Wealth Management LLC purchased a new position in Quest Diagnostics in the second quarter worth approximately $18,558,000. 88.06% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也调整了对 DGX 的持股。Twin Tree Management LP 在第二季度收购了 Quest Diagnostics 的新股份，价值约为 1,895,000 美元。J.Safra 资产管理公司在第二季度将其在 Quest Diagnostics 的股份增加了 8.2%。J.Safra 资产管理公司现在持有 2,553 股医疗研究公司的股票，价值 454,000 美元，此前在此期间又购买了 194 股。TD 资产管理公司在第二季度将其在 Quest Diagnostics 的股份增加了 18.0%。TD 资产管理公司现在持有 121,014 股医疗研究公司的股票，价值 21,738,000 美元，此前在此期间又购买了 18,484 股。Morningstar 投资管理公司在第二季度购买了 Quest Diagnostics 的新股份，价值约为 315,000 美元。最后，Moran Wealth Management LLC 在第二季度购买了 Quest Diagnostics 的新股份，价值约为 18,558,000 美元。88.06% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Quest Diagnostics Stock Up 1.5%</h2>
<div class="lb-trans"><h2>Quest Diagnostics 股票上涨 1.5%</h2>
</div><p>DGX stock opened at $189.71 on Friday. Quest Diagnostics Incorporated has a twelve month low of $146.91 and a twelve month high of $191.49. The company has a current ratio of 1.09, a quick ratio of 0.99 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $21.21 billion, a P/E ratio of 22.72, a PEG ratio of 2.48 and a beta of 0.56. The firm has a 50 day simple moving average of $182.44 and a 200-day simple moving average of $176.13.</p>
<div class="lb-trans"><p>DGX 股票在周五开盘价为 189.71 美元。Quest Diagnostics Incorporated 的 12 个月低点为 146.91 美元，12 个月高点为 191.49 美元。该公司的流动比率为 1.09，速动比率为 0.99，债务与股本比率为 0.71。该公司的市值为 212.1 亿美元，市盈率为 22.72，市盈增长比率为 2.48，贝塔系数为 0.56。该公司的 50 日简单移动平均线为 182.44 美元，200 日简单移动平均线为 176.13 美元。</p>
</div><ul>
<li>LifeMD Shares Come Back to Life on GLP-1 Business Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 因 GLP-1 业务增长而股价回升</li>
</ul>
</div><p>Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.05. The firm had revenue of $2.76 billion for the quarter, compared to analysts' expectations of $2.73 billion. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%.The firm's revenue for the quarter was up 15.2% on a year-over-year basis. During the same period last year, the business posted $2.35 earnings per share. Quest Diagnostics has set its FY 2025 guidance at 9.630-9.830 EPS. On average, equities research analysts predict that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Quest Diagnostics（纽约证券交易所代码：DGX - 获取免费报告）最近在 7 月 22 日宣布了其季度财报。该医疗研究公司报告的每股收益（EPS）为 2.62 美元，超出市场共识预期的 2.57 美元，超出 0.05 美元。该公司在本季度的收入为 27.6 亿美元，而分析师预期为 27.3 亿美元。Quest Diagnostics 的股本回报率为 15.24%，净利润率为 9.01%。该公司的季度收入同比增长 15.2%。去年同期，该公司每股收益为 2.35 美元。Quest Diagnostics 已将其 2025 财年的指导目标设定为每股收益在 9.630 至 9.830 之间。根据平均数据，股票研究分析师预测 Quest Diagnostics Incorporated 在当前财年将发布每股收益 9.7 美元。</p>
</div><h2>Quest Diagnostics Announces Dividend</h2>
<div class="lb-trans"><h2>Quest Diagnostics 宣布分红</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 20th. Investors of record on Friday, October 3rd will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Friday, October 3rd. Quest Diagnostics's payout ratio is currently 38.32%.</p>
<div class="lb-trans"><p>该公司还最近披露了季度分红，将于 10 月 20 日（星期一）支付。10 月 3 日（星期五）登记的投资者将获得每股 0.80 美元的分红。这相当于每年 3.20 美元的分红，分红收益率为 1.7%。除息日为 10 月 3 日（星期五）。Quest Diagnostics 的派息比率目前为 38.32%。</p>
</div><h2>Insider Activity at Quest Diagnostics</h2>
<div class="lb-trans"><h2>Quest Diagnostics 的内部活动</h2>
</div><ul>
<li>Exact Sciences Serves Investors Exactly What They Wished For</li>
</ul>
<div class="lb-trans"><ul>
<li>Exact Sciences 为投资者提供了他们所期望的</li>
</ul>
</div><p>In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 227 shares of the business's stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $188.13, for a total value of $42,705.51. Following the sale, the senior vice president directly owned 38,117 shares in the company, valued at approximately $7,170,951.21. The trade was a 0.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, SVP Karthik Kuppusamy sold 2,210 shares of the business's stock in a transaction dated Thursday, July 31st. The stock was sold at an average price of $170.00, for a total transaction of $375,700.00. Following the completion of the sale, the senior vice president owned 8,450 shares in the company, valued at approximately $1,436,500. This trade represents a 20.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 53,186 shares of company stock worth $9,647,471 over the last ninety days. 8.16% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Quest Diagnostics 的新闻中，高级副总裁 Michael E. Prevoznik 在 9 月 26 日（星期五）出售了 227 股公司的股票。股票以 188.13 美元的平均价格出售，总价值为 42,705.51 美元。出售后，该高级副总裁直接持有 38,117 股公司股票，价值约为 7,170,951.21 美元。此次交易使其持股比例减少了 0.59%。该出售在与证券交易委员会的法律文件中披露，可以通过此链接访问。此外，高级副总裁 Karthik Kuppusamy 在 7 月 31 日（星期四）出售了 2,210 股公司的股票。该股票以 170.00 美元的平均价格出售，总交易额为 375,700.00 美元。出售完成后，该高级副总裁持有 8,450 股公司股票，价值约为 1,436,500 美元。此次交易使其持股比例减少了 20.73%。该出售的披露信息可以在此找到。在过去的九十天里，内部人士共出售了 53,186 股公司股票，价值 9,647,471 美元。8.16% 的股票目前由公司内部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>DGX has been the subject of several recent analyst reports. Weiss Ratings restated a &#34;buy (b)&#34; rating on shares of Quest Diagnostics in a research report on Wednesday, October 8th. Baird R W cut shares of Quest Diagnostics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, August 25th. Truist Financial set a $195.00 price target on shares of Quest Diagnostics in a research note on Tuesday. Wall Street Zen lowered shares of Quest Diagnostics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, August 10th. Finally, Mizuho boosted their price objective on shares of Quest Diagnostics from $190.00 to $210.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $189.06.</p>
<div class="lb-trans"><p>DGX 最近成为几份分析师报告的主题。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Quest Diagnostics 股票的 “买入（b）” 评级。Baird R W 在 8 月 25 日（星期一）的研究报告中将 Quest Diagnostics 的股票评级从 “强力买入” 下调至 “持有”。Truist Financial 在一份研究报告中设定了 Quest Diagnostics 的目标价为 195.00 美元。Wall Street Zen 在 8 月 10 日（星期日）的研究报告中将 Quest Diagnostics 的股票评级从 “买入” 下调至 “持有”。最后，瑞穗证券在一份研究报告中将 Quest Diagnostics 的目标价从 190.00 美元上调至 210.00 美元，并给予该股票 “跑赢大盘” 的评级。一位研究分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，十位分析师给予了持有评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价为 189.06 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on DGX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 DGX 股票分析</strong></p>
</div><h2>Quest Diagnostics Profile</h2>
<div class="lb-trans"><h2>Quest Diagnostics 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.</p>
<div class="lb-trans"><p>Quest Diagnostics Incorporated 在美国和国际上提供诊断测试和服务。该公司开发并提供诊断信息服务，如常规、非常规和高级临床测试、解剖病理测试以及其他诊断信息服务。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Quest Diagnostics</li>
<li>Earnings Per Share Calculator: How to Calculate EPS</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Quest Diagnostics 更好的股票</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>如何投资科技股及值得考虑的顶级科技股</li>
<li>博通与 OpenAI 签署协议：这对 AVGO 股票来说是一个巨大的胜利</li>
<li>投资旅游股票的好处</li>
<li>机构正在推动 CrowdStrike 的下一轮上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=DGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Quest Diagnostics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Quest Diagnostics 吗？</h2>
</div><p>Before you consider Quest Diagnostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Quest Diagnostics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Quest Diagnostics 并不在名单上。</p>
</div><p>While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Quest Diagnostics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

安联资产管理有限公司出售了奎斯特诊疗公司 $DGX 的股票